


The aim of the Fund is to provide a return by way of capital growth and income.
| Name | % Net Assets |
|---|---|
| United Kingdom Gilt 2.25 07/03/2014 | 2.5% |
| United Kingdom Gilt 4 07/09/2016 | 2.3% |
| Netherlands Government Bond 4 15/07/2019 | 2.0% |
| GlaxoSmithKline PLC | 1.8% |
| United Kingdom Gilt 4.5 07/03/2019 | 1.8% |
| BP PLC | 1.8% |
| Bundesrepublik Deutschland 4.75 04/07/2040 | 1.5% |
| Vodafone Group PLC | 1.5% |
| HSBC Holdings PLC | 1.4% |
| AstraZeneca PLC | 1.3% |
| Key | % Net Assets |
|---|---|
| 2.5% | |
| 2.3% | |
| 2.0% | |
| 1.8% | |
| 91.4% |
| Date | 09-Apr-2021 |
|---|---|
| Bid | 132.60p |
| Offer | 132.60p |
| Currency | GBP |
| Change | 0.100p |
| % | 0.08% |
| YTD change | 132.60p |
| YTD % | n/a |
| Fund Inception | 16/09/2002 |
|---|---|
| Fund Manager | Quentin Fitzsimmons |
| TER | - |
| Minimum Investment | |
|---|---|
| Initial | £500000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 1.00% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | 0.10 |
You are here: research